Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 161 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Diabetes Mellitus, Type 1, Type 1 Diabetes Mellitus
Interventions
Diluted Humalog U-200 Insulin, Diluted U-500 Humulin Insulin, Lyumjev U-100 Insulin, Boost Mixed Meal Test
Drug · Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Diabetes Mellitus, Type 2
Interventions
Human Regular U-500 Insulin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
35
States / cities
Mobile, Alabama • Little Rock, Arkansas • Concord, California + 32 more
Recruiting Phase 1 Interventional Accepts healthy volunteers

Graded Insulin Suppression Test P&F

NCT06592261
Conditions
Insulin Resistance, Hyperinsulinemia, Obesity, Healthy
Interventions
Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia), Insulin regular, 32 mU/m2/min (hyperinsulinemia), Octreotide Acetate, 6-45 ng/kg/min, Dextrose 20 % in Water, Glucagon, 0-0.5 ng/kg/min
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Insulin Modulation of fMRI Connectivity in Healthy Adults

NCT02982551
Conditions
Healthy Volunteers
Interventions
Insulin, Taste Task, Magnetic Resonance Imaging, Dextrose
Drug · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years to 30 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Diabetes
Interventions
Wosulin R, Actrapid
Biological
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chula Vista, California
Conditions
Type 2 Diabetes Mellitus
Interventions
NPH and regular insulin, glargine and humalog
Drug
Lead sponsor
Riverside University Health System Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Moreno Valley, California
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin, Oral combined hormonal contraceptives
Drug
Lead sponsor
University of Virginia
Other
Eligibility
40 Years to 49 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Terminated Phase 1 Interventional Accepts healthy volunteers

Molecular Regulation of Muscle Glucose Metabolism

NCT01581736
Conditions
Obesity, Type 2 Diabetes Mellitus
Interventions
U100 Humulin, Exercise
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Scottsdale, Arizona
Conditions
Diabetes Mellitus
Interventions
Insulin, Isophane, insulin glargine
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Falls Church, Virginia
Conditions
Metabolic Syndrome
Interventions
Regular AGE Diet, Low AGE Diet
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
50 Years and older
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Conditions
Type 1 Diabetes Mellitus
Interventions
Family Teamwork Intervention
Behavioral
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
8 Years to 17 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Single Dose Intranasal Insulin On Cognitive Function

NCT00646581
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Placebo, Insulin (Humulin)
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Type 2 Diabetes Mellitus
Interventions
Human insulin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Scottsdale, Arizona
Completed Not applicable Interventional Results available

Regular Insulin vs Rapid Insulin Delivered by V-Go

NCT03495908
Conditions
Type 2 Diabetes, Type 2 Diabetes Mellitus
Interventions
VGo
Device
Lead sponsor
East Coast Institute for Research
Network
Eligibility
21 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Jacksonville, Florida • Macon, Georgia
Conditions
Eating Disorder, Type 1 Diabetes
Interventions
ED/DM Support Group
Behavioral
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed Phase 2 Interventional Results available

Intranasal Insulin in Parkinson's Disease

NCT04251585
Conditions
Parkinson Disease
Interventions
Regular Novolin R, Placebo
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
41 Years to 89 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Saint Paul, Minnesota
Conditions
Diabetes Mellitus
Interventions
Inhaled Human Insulin, Regular Human Insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Hyperglycemia
Interventions
intensive glycemic control, conventional glycemic control
Procedure · Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 95 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Newark, New Jersey
Conditions
Type 2 Diabetes Mellitus
Interventions
NPH/Regular 70/30 mix, insulin aspart protamine/insulin aspart 70/30 mix
Drug
Lead sponsor
Dennis G. Karounos, M.D.
Federal
Eligibility
40 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Insulin
Interventions
Insulin, Regular, Human, Placebo
Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
45 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Conditions
Type 2 Diabetes, Hyperglycemia
Interventions
sliding scale regular insulin (SSRI), Basal Bolus, Basal Plus
Drug
Lead sponsor
Guillermo Umpierrez, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Atlanta, Georgia • Decatur, Georgia • Charleston, South Carolina + 1 more
Conditions
Angina, Unstable, Cardiovascular Diseases, Heart Diseases, Coronary Disease, Myocardial Infarction, Heart Failure, Congestive
Interventions
GIK, Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
30 Years and older
Enrollment
911 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
13
States / cities
Anchorage, Alaska • New Haven, Connecticut • Macon, Georgia + 10 more
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Neural Mechanism of Aldosterone-induced Insulin Resistance

NCT02102243
Conditions
Hypertension
Interventions
DEFINITY® infusion, Human Recombinant Regular Insulin infusion, Dextrose infusion, Flow mediated vasodilation, Endothelial cell collection, Microvascular perfusion assessment using Definity, Microneurography
Drug · Procedure
Lead sponsor
Wanpen Vongpatanasin
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Comparison Study of Insulin Glargine and NPH Insulin

NCT01854723
Conditions
Diabetes
Interventions
Switching to NPH insulin, Continuation of insulin glargine
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
Up to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Portland, Oregon